Standard Chemical & Pharmaceutical Co., Ltd. is a healthcare professional focused on the manufacturing of chemical and pharmaceutical products. The company operates through a network of subsidiaries and offices across Asia, including Standard Chem. & Pharm. Vietnam Co. Ltd., Standard Chem. & Pharm. Philippines, Inc., Standard Pharmaceutical Co., Ltd., and Standard Pharma Holding Co., Ltd. Its business activities are supported by regional offices in Ho Chi Minh City, Hanoi, Taguig, Apia, Bangkok, and Shanghai. The company emphasizes strict quality assurance systems and adherence to national and international standards in its production processes.
More
Summarised from the company's own disclosures, fiscal year ended Oct 2026
Industry
Drug Manufacturers - General
Homepage
standard.com.tw
Sector
Healthcare
IR page
standard.com.tw/investor-f-law.php
Tags
chemical manufacturing, pharmaceuticals, quality assurance, healthcare, api manufacturing, Standard Chem. & Pharm. Vietnam Co. Ltd., Standard Chem. & Pharm. Philippines Inc., Standard Pharmaceutical Co. Ltd., Standard Pharma Holding Co. Ltd.
More
Press page
—
Metrics
Market cap
NT$ 10.711B
Market cap (USD)
$ 325.105M
P/E
10.46
PEG
2.38
P/BV
1.66
P/S
1.48
P/OCF
6.32
P/FCF
—
Dividend yield
—
Turnover / mcap
—
ROE
15.4%
ROI
15.1%
ROIC
18.5%
Profit margin
13.2%
Revenue growing
Yes
Profits growing
Yes
Revenue up 3y
Yes
Revenue up 5y
Yes
Earnings growth 3y (net profit CAGR)
4.4%
Profitable
Yes
Margin expanding
No
Buying back stock
No
Diluting (TTM)
Yes
Debt/Equity
—
Podcast bulls (TTM)
Sign up
Podcast bears (TTM)
Sign up
Podcast sentiment (TTM)
Sign up
Podcast sentiment % (TTM)
Sign up
News sentiment (TTM)
0
Quality score
56.3%
Buys, 1w
Sign up
Buys, 1m
Sign up
Buys, 1y
Sign up
Sells, 1w
Sign up
Sells, 1m
Sign up
Sells, 1y
Sign up
Sign up to see this company's insider trades
Fundamentals
(all numbers in TWD)
Compare
All 31 figures
Annual
Quarterly
Compare with
×
Revenue
7.023B
6.789B
6.24B
5.851B
4.604B
4.305B
3.937B
3.573B
3.849B
3.674B
3.321B
3.296B
3.054B
3.374B
3.332B
2.894B
Net profit
927.659M
880.501M
834.886M
815.408M
706.734M
524.172M
376.482M
374.359M
363.286M
340.216M
347.894M
374.235M
298.386M
271.426M
246.748M
210.053M
Share price
58.9
61.9
65.9
61.5
43.1
37.7
—
—
—
—
—
—
—
—
—
—
Price performance 12m
-0.05
-0.06
0.07
0.43
0.14
—
—
—
—
—
—
—
—
—
—
—
Sign up to see institutional holdings
Sign Up
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up
Material information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS.
AI comment
This is a routine notice announcing the date, time, and location of an upcoming investor relations meeting to discuss the first three quarters of 2026. It provides no new financial data, guidance, or operational updates, only logistical details for a future event.
AI comment
This is a routine internal corporate restructuring involving the simple merger of two wholly-owned subsidiaries (Yifa and Shengxun) to simplify the organizational structure. The filing explicitly states it does not affect shareholder equity, involves no external transaction value, and is a standard administrative step with no new financial impact or strategic revelation for the parent company.
AI comment
The company confirms that a subsidiary's plan to address an excess fund lending limit has been completed following the bankruptcy liquidation of the debtor. The parent company states it has already recognized the cumulative losses and that there is no further material impact on its financial position, making this a routine procedural closure of a known issue.
AI comment
This is a routine filing announcing that the board has approved the third-quarter consolidated financial report. It serves as a formal notice of the reporting period and approval date without providing new analytical insights or unexpected performance data in the headline or summary.
AI comment
The company's subsidiary is renewing a lease for office space from a related party (parent company) for approximately 105,000 TWD per month, totaling a right-of-use asset value of ~5.7 million TWD. This is a routine operational expense and administrative filing with no material impact on the company's 10.8 billion TWD market cap or financial position.
AI comment
The company confirms that a subsidiary's plan to address an excess fund lending limit has been completed following the bankruptcy liquidation of the debtor. The text explicitly states the event has no material impact on the company's financials, making this a routine formal filing.
AI comment
Standard Chemical is acquiring the remaining 8.76% of its subsidiary Yifa Technology for approximately 37.5 million TWD (roughly 0.35% of market cap) to simplify the corporate structure. The amount is minor relative to the company's size, and the transaction is funded by existing cash with no dilution, representing a routine administrative consolidation.
AI comment
The company reports that a subsidiary's loan to another entity exceeded regulatory limits due to the borrower's insolvency and subsequent bankruptcy proceedings. While the financial impact is stated to be immaterial to the parent company (approx. 8.7M TWD vs 10.8B TWD market cap), the event involves a regulatory breach regarding fund lending and confirms a loss on the subsidiary's investment, constituting a notable negative operational and compliance issue.
AI comment
This is a routine filing announcing that the board has approved the Q2 consolidated financial report. It does not contain the actual performance figures or commentary required to assess value impact, serving only as a procedural notice.
AI comment
This is a routine notice announcing the date of the upcoming board meeting to review the Q2 financial results. It provides no financial data or strategic updates, only procedural information.
AI comment
The company issued a routine clarification stating that it has not made any official financial forecasts, despite media reports quoting the chairman's growth targets. This is a formal notice correcting misinformation rather than a substantive business update, so it has no impact on valuation.
AI comment
This is a routine administrative filing announcing the record dates and logistics for a previously approved dividend distribution (TWD 2.00 cash and 1.00 stock per share). It provides no new information regarding the company's value or performance.
AI comment
The shareholder meeting approved lifting the non-compete restriction for Director Wang Hui-jun, a routine corporate governance filing with no stated impact on financials or operations.
AI comment
This is a routine regulatory filing updating the status of a previously announced improvement plan regarding a subsidiary's loan limit breach. The company states it has already recognized the losses and that there is no material impact on its financials, making this a formal notice with no new value-relevant information.
AI comment
This is a routine regulatory filing announcing that the board has approved the Q1 consolidated financial report. It does not contain the actual financial results or commentary needed to assess performance, serving only as a procedural notice.
AI comment
This is a routine announcement of the outcomes of the Annual General Meeting, including the approval of financial statements, dividend distribution, and charter amendments. These are standard corporate formalities that convey no new information regarding the company's value or future prospects.
AI comment
This is a routine notice announcing the date of the board meeting to review Q1 financials. It contains no financial data, guidance, or operational updates, so it has no immediate impact on valuation.
AI comment
The company is changing its share registrar due to a merger between the previous agents, which is a routine administrative matter with no impact on company value.
AI comment
This is a routine notice announcing the date, time, and location of a corporate presentation (investor day) for the 2024 fiscal year. It provides no new financial data, guidance, or strategic updates, merely directing investors to the public information station for details. Such administrative filings are neutral.
AI comment
The board approved a cash dividend of 2.00 TWD per share and a stock dividend of 1.00 TWD per share for FY2024, totaling approximately 357.4M TWD in cash, which represents a modest return of capital and signals confidence in the company's cash flow.
Show all 20 news items
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat.
Shared by
Asian Century Stocks and
Uncovered Thai Stocks .
Thank you.
Base
Enforce Recency
Overview
Bull Bear
Competitive Advantages
Supply Chain
Segments
Earnings Results
Earnings Calls
Management
Stock Price Analysis
Comps
Forward Projection
Red Flags
Management Questions
Devils Advocate
Constraints
Share Value Compliance
Equity Research
Standard Chemical & Pharmaceutical Co., Ltd. (ticker 1720.TW), listed in Taiwan.
Copy
Clear
Copied
ETFs Holding Standard Chemical & Pharmaceutical Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
DFEV
0.00%
45,500
$ 75.765K
Nov 12, 2026
DFEM
0.00%
145,200
$ 241.783K
Nov 12, 2026
DFSE
0.00%
6,600
$ 10.99K
Nov 12, 2026
DFAE
0.00%
97,400
$ 162.188K
Nov 12, 2026
DFAX
0.00%
66,363
$ 110.506K
Nov 12, 2026
AVEM
0.00%
17,600
$ 29.495K
Nov 16, 2026
AVEE
0.00%
2,200
$ 3,686.86
Nov 16, 2026
AVXC
0.00%
5,200
$ 8,714.40
Nov 16, 2026